— Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported earnings of $2.71 per share in the fourth-quarter 2019, vs. $2.60 per share expected.
— Total revenue rose 23% to $1.38 billion, vs. $1.31 billion expected. SOLIRIS net sales rose 11% to $3.94 billion.
— For FY20, Alexion expects revenues of $5.50 – $5.56 billion. Adjusted EPS is projected to be $10.65 to $10.85.
— ALXN stock gained 1.8% during pre-market hours immediately following the announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
What to look for when Hormel Foods (HRL) reports Q4 2023 earnings
Shares of Hormel Foods Corporation (NYSE: HRL) were down over 1% on Monday. The stock has dropped 29% year-to-date. The food company is set to report its fourth quarter 2023 earnings
Kroger set to report Q3 results. Here’s everything you need to know
The Kroger Co. (NYSE: KR), a leading grocery retailer that operates both in-store and online, will be reporting earnings this week. The company, which is preparing to acquire rival retailer
Earnings Preview: Salesforce will likely deliver another strong quarter
Salesforce, Inc. (NYSE: CRM) achieved accelerated sales growth and profitability in recent quarters, in line with its transformation goal. The customer relationship management platform bets on new opportunities in generative
